# Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

> **NCT05651022** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Indaptus Therapeutics, Inc** · enrollment: 120 (estimated)

## Conditions studied

- Solid Tumor, Adult
- HCC - Hepatocellular Carcinoma
- CRC (Colorectal Cancer)
- Pancreatic Adenocarcinoma
- NSCLC Non-small Cell Lung Cancer
- Squamous Cell Cancer of the Head and Neck
- UC (Urothelial Cancer)
- MSI-H Cancer

## Interventions

- **DRUG:** Decoy20
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05651022
- **Lead sponsor:** Indaptus Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-28
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05651022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05651022, "Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05651022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*